

ALLERGAN INC  
Form S-8 POS  
March 17, 2015

As filed with the Securities and Exchange Commission on March 17, 2015

Registration No. 333-193149  
Registration No. 333-174025  
Registration No. 333-158925  
Registration No. 333-150668  
Registration No. 333-133817  
Registration No. 333-117939  
Registration No. 333-117937  
Registration No. 333-117936  
Registration No. 333-117935  
Registration No. 333-65176  
Registration No. 333-43584  
Registration No. 333-43580  
Registration No. 333-94157  
Registration No. 333-94155  
Registration No. 333-70407  
Registration No. 333-64559  
Registration No. 333-25891  
Registration No. 333-09091  
Registration No. 333-04859  
Registration No. 33-66874  
Registration No. 33-48908  
Registration No. 33-44770  
Registration No. 33-29528  
Registration No. 33-29527

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OF 1933

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-193149

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-174025**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-158925**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-150668**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-133817**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-117939**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-117937**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-117936**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-117935**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-65176**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-43584**  
**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-43580**  
**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-94157**  
**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-94155**  
**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-70407**  
**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-64559**  
**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-25891**  
**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-09091**  
**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-04859**  
**Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 33-66874**  
**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 33-48908**  
**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 33-44770**  
**Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 33-29528**  
**Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 33-29527**

**ALLERGAN, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or Other Jurisdiction of**  
**Incorporation or Organization)**

**95-01622442**  
**(I.R.S. Employer**  
**Identification No.)**

Edgar Filing: ALLERGAN INC - Form S-8 POS

2525 Dupont Drive

Irvine, California 92612-1599

(Address of Principal Executive Offices)

**ALLERGAN IRISH SHARE PARTICIPATION SCHEME**

**ALLERGAN, INC. 2011 INCENTIVE AWARD PLAN**

**ALLERGAN, INC. SAVINGS AND INVESTMENT PLAN (RESTATED 2008), AS AMENDED**

**ALLERGAN, INC. 2008 INCENTIVE AWARD PLAN**

**ALLERGAN, INC. 2003 NONEMPLOYEE DIRECTOR EQUITY INCENTIVE PLAN**

**ALLERGAN, INC. EXECUTIVE DEFERRED COMPENSATION PLAN (AMENDED AND RESTATED**

**AS OF JANUARY 1, 2003), AS AMENDED**

**ALLERGAN, INC. SAVINGS AND INVESTMENT PLAN (RESTATED 2003), AS AMENDED**

**ALLERGAN, INC. 2003 NONEMPLOYEE DIRECTOR EQUITY INCENTIVE PLAN**

**ALLERGAN, INC. 1989 INCENTIVE COMPENSATION PLAN, AS AMENDED**

**ALLERGAN, INC. 2001 PREMIUM PRICED STOCK OPTION PLAN**

**ALLERGAN PHARMACEUTICALS (IRELAND) LTD., INC. SAVINGS RELATED SHARE OPTION**

**SCHEME (2000)**

**ALLERGAN, INC. 1989 NONEMPLOYEE DIRECTOR STOCK PLAN**

**ALLERGAN, INC. EXECUTIVE DEFERRED COMPENSATION PLAN**

**ALLERGAN, INC. DEFERRED DIRECTORS FEE PROGRAM**

**ALLERGAN, INC. STOCK PRICE INCENTIVE PLAN**

**ALLERGAN, INC. 1989 INCENTIVE COMPENSATION PLAN**

**ALLERGAN, INC. SAVINGS AND INVESTMENT PLAN**

**EMPLOYEE RECOGNITION AWARD PLAN**  
**1989 INCENTIVE COMPENSATION PLAN**  
**SAVINGS AND INVESTMENT PLAN**  
**1989 NONEMPLOYEE DIRECTOR STOCK PLAN**  
**(Full Title of the Plans)**

**A. Robert D. Bailey**  
**Chief Legal Officer and Corporate Secretary**

**Actavis plc**  
**Morris Corporate Center III**  
**400 Interpace Parkway**  
**Parsippany, New Jersey 07054**  
**(862) 261-7000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

|                         |                                     |                           |                          |
|-------------------------|-------------------------------------|---------------------------|--------------------------|
| Large accelerated filer | <input checked="" type="checkbox"/> | Accelerated filer         | <input type="checkbox"/> |
| Non-accelerated filer   | <input type="checkbox"/>            | Smaller reporting company | <input type="checkbox"/> |

(Do not check if a smaller reporting company)

### DEREGISTRATION OF SECURITIES

Allergan, Inc. (the Registrant ), is filing this Post-Effective Amendment to each of the following Registration Statements on Form S-8 (collectively, the Registration Statements ) to deregister any and all securities that remain unsold under such Registration Statements.

- (1) Registration Statement No. 333-193149, filed with the Securities Exchange Commission (the Commission ) on December 31, 2013, registering the offer and sale of 150,000 shares of the Registrant's common stock, par value \$0.01 per share (the Common Stock ), issuable pursuant to the Registrant's Allergan Irish Share Participation Scheme;
- (2) Registration Statement No. 333-174025, filed with the Commission on May 6, 2011, registering the offer and sale of 21,821,946 shares of the Registrant's Common Stock issuable pursuant to the Registrant's 2011 Incentive Award Plan;
- (3) Registration Statement No. 333-158925, filed with the Commission on April 30, 2009, registering the offer and sale of 2,500,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's Savings and Investment Plan (Restated 2008), as amended;
- (4) Registration Statement No. 333-150668, filed with the Commission on May 6, 2008, registering the offer and sale of 22,500,000 shares of the Registrant's Common Stock issuable pursuant to the Registrant's 2008 Incentive Award Plan;
- (5) Registration Statement No. 333-133817, filed with the Commission on May 4, 2006, registering the offer and sale of 350,000 shares of the Registrant's Common Stock issuable pursuant to the Registrant's 2003 Nonemployee Director Equity Incentive Plan;
- (6) Registration Statement No. 333-117939, filed with the Commission on August 4, 2004, registering \$65,000,000 in deferred compensation obligations of the Registrant pursuant to the Registrant's Executive Deferred Compensation Plan (Amended and Restated as of January 1, 2003), as amended;
- (7) Registration Statement No. 333-117937, filed with the Commission on August 4, 2004, registering the offer and sale of 500,000 shares of the Registrant's Common Stock issuable pursuant to the Registrant's Savings and Investment Plan (Restated 2003), as amended;
- (8) Registration Statement No. 333-117936, filed with the Commission on August 4, 2004, registering the offer and sale of 250,000 shares of the Registrant's Common Stock issuable pursuant to the Registrant's 2003 Nonemployee Director Equity Incentive Plan;
- (9)

Edgar Filing: ALLERGAN INC - Form S-8 POS

Registration Statement No. 333-117935, filed with the Commission on August 4, 2004, registering the offer and sale of 16,000,000 shares of the Registrant s

Common Stock, issuable pursuant to the Registrant's 1989 Incentive Compensation Plan, as amended;

- (10) Registration Statement No. 333-65176, filed with the Commission on July 16, 2001, registering the offer and sale of 2,400,000 shares of the Registrant's Common Stock issuable pursuant to the Registrant's 2001 Premium Priced Stock Option Plan;
- (11) Registration Statement No. 333-43584, filed with the Commission on August 11, 2000, registering the offer and sale of 300,000 shares of the Registrant's Common Stock issuable pursuant to the Registrant's Allergan Pharmaceuticals (Ireland) Ltd., Inc. Savings Related Share Option Scheme (2000);
- (12) Registration Statement No. 333-43580, filed with the Commission on August 11, 2000, registering the offer and sale of 50,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's 1989 Nonemployee Director Stock Plan;
- (13) Registration Statement No. 333-94157, filed with the Commission on January 6, 2000, registering \$12,500,000 in deferred compensation obligations of the Registrant pursuant to the Registrant's Executive Deferred Compensation Plan;
- (14) Registration Statement No. 333-94155, filed with the Commission on January 6, 2000, registering \$26,000,000 in deferred compensation obligations of the Registrant pursuant to the Registrant's Deferred Directors' Fee Program, as well as the offer and sale of 500,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's Deferred Directors' Fee Program;
- (15) Registration Statement No. 333-70407, filed with the Commission on January 11, 1999, registering the offer and sale of 18,431 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's Stock Price Incentive Plan;
- (16) Registration Statement No. 333-64559, filed with the Commission on September 29, 1998, registering the offer and sale of 50,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's 1989 Nonemployee Director Stock Plan;
- (17) Registration Statement No. 333-25891, filed with the Commission on April 25, 1997, registering the offer and sale of 5,000,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's 1989 Incentive Compensation Plan;
- (18) Registration Statement No. 333-09091, filed with the Commission on July 29, 1996, registering the offer and sale of 500,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's Savings and Investment Plan;

Edgar Filing: ALLERGAN INC - Form S-8 POS

- (19) Registration Statement No. 333-04859, filed with the Commission on May 31, 1996, registering the offer and sale of 150,000 shares of the Registrant's Common

Stock, issuable pursuant to the Registrant's Allergan Irish Share Participation Scheme;

- (20) Registration Statement No. 33-66874, filed with the Commission on August 2, 1993, registering the offer and sale of 100,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's Employee Recognition Award Plan;
- (21) Registration Statement No. 33-48908, filed with the Commission on June 30, 1992, registering the offer and sale of 5,000,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's 1989 Incentive Compensation Plan;
- (22) Registration Statement No. 33-44770, filed with the Commission on December 24, 1991, registering the offer and sale of 470,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's Savings and Investment Plan;
- (23) Registration Statement No. 33-29528, filed with the Commission on June 26, 1989, registering the offer and sale of 500,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's Savings and Investment Plan; and
- (24) Registration Statement No. 33-29527, filed with the Commission on June 26, 1989, registering the offer and sale of 5,050,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's 1989 Incentive Compensation Plan and 1989 Nonemployee Director Stock Plan.

On March 17, 2015, pursuant to the Agreement and Plan of Merger, dated November 16, 2014, among the Registrant, Actavis plc, an Irish public limited company (Actavis), and Avocado Acquisition Inc., a Delaware corporation and an indirect wholly owned subsidiary of Actavis (Merger Sub), Registrant merged with and into Merger Sub, with the Registrant being the surviving entity (the Merger).

In connection with the Merger, the Registrant has terminated all offers and sales of its securities registered pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. In accordance with undertakings made by the Registrant to remove from registration, by means of a post-effective amendment, any of the securities which remain unsold at the termination of the offerings, the Registrant hereby removes from registration any and all securities registered but unsold under the Registration Statements as of the date hereof.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Parsippany, State of New Jersey on the 17th day of March 2015.

**ALLERGAN, INC.**

| <b>Signature</b>                               | <b>Title</b>  | <b>Date</b>    |
|--|---|----------------|
| /s/ A. Robert D. Bailey<br>A. Robert D. Bailey | President and Chairman of the Board<br><br><i>(Principal Executive Officer)</i> | March 17, 2015 |
| /s/ Steve Kaufhold<br>Steve Kaufhold           | Treasurer<br><i>(Principal Financial and Accounting Officer)</i>                | March 17, 2015 |
| /s/ Maria Teresa Hilado<br>Maria Teresa Hilado | Director  | March 17, 2015 |